HC Wainwright set a $2.00 price target on CytoDyn (OTCMKTS:CYDY) in a report issued on Wednesday. The firm currently has a buy rating on the biotechnology company’s stock.
Separately, Zacks Investment Research upgraded shares of CytoDyn from a hold rating to a buy rating and set a $0.75 price target on the stock in a research note on Tuesday, September 18th.
Shares of CYDY stock opened at $0.54 on Wednesday. The company has a market cap of $133.15 million, a P/E ratio of -1.86 and a beta of 0.37. CytoDyn has a 12 month low of $0.40 and a 12 month high of $0.84.
CytoDyn (OTCMKTS:CYDY) last announced its quarterly earnings results on Tuesday, October 9th. The biotechnology company reported ($0.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.01). As a group, research analysts predict that CytoDyn will post -0.2 earnings per share for the current fiscal year.
CytoDyn Inc, a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease.
Read More: Price to Earnings Ratio (PE)
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.